The flow cytometry analysis revealed that the number of integrin β4+ CTCs was higher in patients with metastases, as well as more aggressive molecular subtypes of breast cancer (luminal (HER2+) and TNBC) compared to luminal A/B (HER2−) breast cancer. The gene discussed is ERBB2; the disease is breast cancer.